JP2010509369A - 加齢黄斑変性症を処置するための方法 - Google Patents

加齢黄斑変性症を処置するための方法 Download PDF

Info

Publication number
JP2010509369A
JP2010509369A JP2009536520A JP2009536520A JP2010509369A JP 2010509369 A JP2010509369 A JP 2010509369A JP 2009536520 A JP2009536520 A JP 2009536520A JP 2009536520 A JP2009536520 A JP 2009536520A JP 2010509369 A JP2010509369 A JP 2010509369A
Authority
JP
Japan
Prior art keywords
antibody
vegf
antibodies
domain
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009536520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509369A5 (enExample
Inventor
ナベード シャムス，
Original Assignee
ジェネンテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック インコーポレイテッド filed Critical ジェネンテック インコーポレイテッド
Publication of JP2010509369A publication Critical patent/JP2010509369A/ja
Publication of JP2010509369A5 publication Critical patent/JP2010509369A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009536520A 2006-11-10 2007-11-09 加齢黄斑変性症を処置するための方法 Pending JP2010509369A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86538006P 2006-11-10 2006-11-10
PCT/US2007/084320 WO2008063932A2 (en) 2006-11-10 2007-11-09 Method for treating age-related macular degeneration

Publications (2)

Publication Number Publication Date
JP2010509369A true JP2010509369A (ja) 2010-03-25
JP2010509369A5 JP2010509369A5 (enExample) 2010-12-02

Family

ID=39323041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536520A Pending JP2010509369A (ja) 2006-11-10 2007-11-09 加齢黄斑変性症を処置するための方法

Country Status (6)

Country Link
US (2) US20100111963A1 (enExample)
EP (1) EP2089059A2 (enExample)
JP (1) JP2010509369A (enExample)
AU (1) AU2007323925A1 (enExample)
CA (1) CA2666709A1 (enExample)
WO (1) WO2008063932A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105610A1 (ja) * 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
JP2014503555A (ja) * 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2016521712A (ja) * 2013-06-07 2016-07-25 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
JP2016532658A (ja) * 2013-10-08 2016-10-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 眼病の処置のためのＮ−（４−ｔｅｒｔ−ブチルベンジル）−３−クロロ−Ｎ−［２−（４−クロロ−３−エチル−フェニル）−エチル］−２−フルオロ−５−トリフルオロメチル−ベンズアミドの使用
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11769597B2 (en) 2015-12-03 2023-09-26 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US12280093B2 (en) 2017-11-30 2025-04-22 Regenron Pharmaceuticals, Inc. Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) * 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
ES2468827T3 (es) * 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
KR20140008303A (ko) * 2010-10-27 2014-01-21 노파르티스 아게 안구 혈관 질환의 치료를 위한 투여 요법
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
BR112015003658B1 (pt) * 2012-08-21 2022-09-27 Opko Pharmaceuticals, Llc Formulação oftálmica, uso da dita formulação no tratamento de doença oftálmica do segmento posterior, formulação de lipossomas e suspensão oftálmica lipossomal
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US20180280414A1 (en) * 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
KR101880670B1 (ko) * 2015-11-06 2018-08-16 주식회사 모다이노칩 압력 센서를 구비하는 전자기기
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3515536A1 (en) * 2016-09-19 2019-07-31 Lupin Limited In-line filter for protein/peptide drug administration
MX2020007948A (es) 2018-02-02 2020-12-10 Univ Kyoto Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190317A (en) * 1877-05-01 Improvement in barbers chairs
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
MXPA04007583A (es) * 2002-02-11 2005-04-25 Genentech Inc Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN5010000495; ＨＥＩＥＲ　Ｊ　Ｓ: ＩＯＶＳ Ｖ４６　Ｎ．ＳＵＰＰＬ．Ｓ, 2005, ＡＢＳＴＲＡＣＴ　１３９３ *
JPN5010000496; ［ＯＮＬＩＮＥ］ , 20060603 *
JPN5010000498; ＲＯＳＥＮＦＥＬＤ　Ｐ: ＲＥＶＩＥＷ　ＯＦ　ＯＰＨＴＨＡＬＭＯＬＯＧＹ　［ＯＮＬＩＮＥ］ Ｖ１２　Ｎ１２, 20051201 *
JPN6012064424; ＬＵＣＥＮＴＩＳ　Ｐｒｅｓｃｒｉｂｉｎｇ　Ｉｎｆｏｒｍａｔｉｏｎ　-　Ｇｅｎｅｎｔｅｃｈ , 200610 *
JPN6012064426; 臨床眼科，　Ｖｏｌ．５８　Ｎｏ．７，　ｐ．１２６５-３９　（２００４） *
JPN6012064428; 臨床眼科，　Ｖｏｌ．６０　Ｎｏ．４，　ｐ．５７７-８０　（２００６　Ａｐｒ） *
JPN6012064430; 眼科，　Ｖｏｌ．４２，　ｐ．８８７-８９３　（２０００） *
JPN6012064432; Ｂｒ　Ｊ　Ｏｐｈｔｈａｌｍｏｌ．，　Ｖｏｌ．８９　ｐ．３１６-２０　（２００５） *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10888601B2 (en) 2011-01-13 2021-01-12 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US10828345B2 (en) 2011-01-13 2020-11-10 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US9254338B2 (en) 2011-01-13 2016-02-09 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US12268730B2 (en) 2011-01-13 2025-04-08 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11986511B2 (en) 2011-01-13 2024-05-21 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
JP2017061467A (ja) * 2011-01-13 2017-03-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
US9669069B2 (en) 2011-01-13 2017-06-06 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11975045B2 (en) 2011-01-13 2024-05-07 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11253572B2 (en) 2011-01-13 2022-02-22 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US10857205B2 (en) 2011-01-13 2020-12-08 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
JP2014503555A (ja) * 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
US11730794B2 (en) 2011-01-13 2023-08-22 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US10130681B2 (en) 2011-01-13 2018-11-20 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11559564B2 (en) 2011-01-13 2023-01-24 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11707506B2 (en) 2011-01-13 2023-07-25 Regeneren Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
WO2012105610A1 (ja) * 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
JP2016521712A (ja) * 2013-06-07 2016-07-25 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
JP2016532658A (ja) * 2013-10-08 2016-10-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 眼病の処置のためのＮ−（４−ｔｅｒｔ−ブチルベンジル）−３−クロロ−Ｎ−［２−（４−クロロ−３−エチル−フェニル）−エチル］−２−フルオロ−５−トリフルオロメチル−ベンズアミドの使用
US11769597B2 (en) 2015-12-03 2023-09-26 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US12280093B2 (en) 2017-11-30 2025-04-22 Regenron Pharmaceuticals, Inc. Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US12116622B2 (en) 2018-05-25 2024-10-15 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US12571027B2 (en) 2018-05-25 2026-03-10 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

Also Published As

Publication number Publication date
US20100111963A1 (en) 2010-05-06
AU2007323925A1 (en) 2008-05-29
WO2008063932A3 (en) 2008-09-04
US20120009185A1 (en) 2012-01-12
WO2008063932A2 (en) 2008-05-29
EP2089059A2 (en) 2009-08-19
CA2666709A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
AU2005299701B2 (en) Method for treating intraocular neovascular diseases
US20120009185A1 (en) Method for treating age-related macular degeneration
KR102724014B1 (ko) 안 질환의 치료 방법
AU2021286278B2 (en) Methods for treating ocular diseases
JP2017536414A (ja) 血管性眼疾患を処置するための方法および製剤
CN104066448A (zh) 眼病的治疗
WO2007011873A2 (en) Method for treating intraocular neovascular diseases
AU2011101625A4 (en) Method for treating intraocular neovascular diseases
AU2012100335B4 (en) Method for treating intraocular neovascular diseases
AU2011101626B4 (en) Method for treating intraocular neovascular diseases
AU2011101623A4 (en) Method for treating intraocular neovascular diseases
AU2011101627B4 (en) Method for treating intraocular neovascular diseases
AU2011101622A4 (en) Method for treating intraocular neovascular diseases
AU2011101624B4 (en) Method for treating intraocular neovascular diseases
HK1102106B (en) Method for treating intraocular neovascular diseases
HK1151222A (en) Method for treating intraocular neovascular diseases
HK1151219A (en) Method for treating intraocular neovascular diseases
HK1151989A (en) Method for treating intraocular neovascular diseases
HK1241908A1 (en) Methods and formulations for treating vascular eye diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130308

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140225